Subgroup-specific structural variation across 1,000 medulloblastoma genomes

Citations Over TimeTop 1% of 2012 papers

Abstract

Medulloblastoma, the most common malignant paediatric brain tumour, is currently treated with nonspecific cytotoxic therapies including surgery, whole-brain radiation, and aggressive chemotherapy. As medulloblastoma exhibits marked intertumoural heterogeneity, with at least four distinct molecular variants, previous attempts to identify targets for therapy have been underpowered because of small samples sizes. Here we report somatic copy number aberrations (SCNAs) in 1,087 unique medulloblastomas. SCNAs are common in medulloblastoma, and are predominantly subgroup-enriched. The most common region of focal copy number gain is a tandem duplication of SNCAIP, a gene associated with Parkinson's disease, which is exquisitely restricted to Group 4α. Recurrent translocations of PVT1, including PVT1-MYC and PVT1-NDRG1, that arise through chromothripsis are restricted to Group 3. Numerous targetable SCNAs, including recurrent events targeting TGF-β signalling in Group 3, and NF-κB signalling in Group 4, suggest future avenues for rational, targeted therapy.

Related Papers

• → Noncoding RNA PVT1 in osteosarcoma: The roles of lncRNA PVT1 and circPVT1(2022)11 cited
• → The formation of variants with a reversion of properties of transformed cells. vi. stability of the reverted state(1972)21 cited
• → The influence of deficiencies in DNA-repair on MR-mediated reversion of an insertion-sequence mutation in Drosophila melanogaster(1983)13 cited
• → The formation of variants with a reversion of properties of transformed cells. VII. Chromosome numbers and re‐reversion in subtetraploid variants(1972)2 cited
• Effects of anti-reversion agent SR534 on properties of NR compound(2009)